FDA Clears First Oral Wegovy, Fueling 8% Stock Rally
Novo Nordisk secured FDA approval for the first oral version of Wegovy, creating the U.S.’s inaugural oral GLP-1 weight management therapy. The approval sparked an 8% one-day share surge and gives the company a first-mover advantage to compete with Eli Lilly and expand manufacturing scale for broader patient access.
1. FDA Approves Oral Wegovy Pill
The U.S. Food and Drug Administration has granted approval for an oral formulation of Wegovy, making Novo Nordisk the first company to market a GLP-1 weight-management therapy in pill form. This milestone follows extensive Phase III data showing an average 16.6% reduction in body weight over 68 weeks, with more than one-third of patients achieving at least 20% weight loss. The oral pill addresses patient reluctance toward weekly injections and leverages the established Wegovy brand, which generated over $6 billion in sales last year in its injectable form.
2. Shares Surge on First-Mover Advantage
Novo Nordisk's share price jumped by 8% in a single trading session after the FDA announcement, reflecting investor optimism about market expansion and cost advantages of oral manufacturing. Analysts estimate the oral version could attract an additional 1.5 million patients over the next three years, potentially adding $3 billion to annual revenue. Lower production costs and broader third-party coverage may further accelerate sales growth.
3. Competitive Landscape Tightens
Despite the lead, Novo Nordisk faces imminent competition from Eli Lilly’s orforglipron, which holds an expedited review voucher and could receive approval by March. Lilly’s oral candidate demonstrated sustained weight loss after switching from injectables, with Phase II patients maintaining a 12% reduction at 52 weeks. Market share in anti-obesity therapies is already tightly contested: Lilly’s Zepbound overtook Wegovy in quarterly sales last quarter, underscoring that early entry does not guarantee dominance.
4. Valuation and Growth Outlook
Novo Nordisk trades at roughly 13 times projected earnings, below the 18x average for large cap healthcare peers. Beyond oral Wegovy, the company has filed for approval of CagriSema, which outperformed semaglutide in head-to-head trials with up to 20% mean weight loss, and recently expanded Wegovy labels to include metabolic dysfunction-associated steatohepatitis, a market expected to add over $1 billion in annual sales. With an 81.9% gross margin, a 3.3% dividend yield, and a pipeline of mid- and late-stage candidates, Novo Nordisk remains positioned for long-term leadership in the fast-growing weight-management sector.